Roche (RHHBY) And Syrrx, Inc. Initiate Strategic Alliance In Diabetes And Cancer
10/19/2005 5:11:16 PM
Roche and Syrrx today announced a strategic partnership focused on the discovery and development of drug candidates to treat cancer and type 2 diabetes. The preclinical programs focus on two emerging targets, HDAC, an oncology target that regulates gene transcription and 11-beta HSD-1, a metabolic target that reduces the production of cortisol, a hormone overexpressed in diabetics. The agreement reflects Syrrx's evolution as a structure-based drug discovery and development company, builds on the technology alliance Roche and Syrrx signed in May 2002 and complements Roche's internal HDAC and 11-beta HSD-1 programs.
comments powered by